Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Surgery today (Print)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00595-016-1338-0PMID 27130464
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.

  2017cited by this paper
• Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

  2016cited by this paper
• Neutrophil/lymphocyte ratio predicts the prognosis in esophageal squamous cell carcinoma patients

  2016cited by this paper
• Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.

  2016cited by this paper
• Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus.

  2015cited by this paper
• A phase I/II study of divided-dose docetaxel, cisplatin, and fluorouracil (DCF) for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.

  2015cited by this paper
• Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis

  2014cited by this paper
• Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients

  2014cited by this paper
• Outcomes of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Esophagectomy in Patients with Resectable Node-Positive Esophageal Cancer

  2014cited by this paper
• Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum–paclitaxel chemotherapy

  2014cited by this paper
• Outcomes of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Esophagectomy in Patients with Resectable Node-Positive Esophageal Cancer

  2014cited by this paper
• BRCA1 mRNA Expression as a Predictive and Prognostic Marker in Advanced Esophageal Squamous Cell Carcinoma Treated with Cisplatin- or Docetaxel-Based Chemotherapy/Chemoradiotherapy

  2013cited by this paper
• Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma

  2013cited by this paper
• ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.

  2013cited by this paper
• mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer.

  2011cited by this paper
• Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.

  2011cited by this paper
• Class III β-tubulin (TUBB3): more than a biomarker in solid tumors?

  2011cited by this paper
• A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)

  2011cited by this paper
• Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy.

  2011cited by this paper
• Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.

  2010cited by this paper
• Excision-repair cross-complementing 1 predicts response to cisplatin-based neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.

  2009cited by this paper
• Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine.

  2009cited by this paper
• ERCC1 and XRCC1 Gene Polymorphisms Predict Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer

  2009cited by this paper
• The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer

  2009cited by this paper
• Japanese Classification of Esophageal Cancer, tenth edition: part I

  2009cited by this paper
• ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.

  2008cited by this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cited by this paper
• Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.

  2006cited by this paper
• Association of Pretherapeutic Expression of Chemotherapy-Related Genes with Response to Neoadjuvant Chemotherapy in Barrett Carcinoma

  2005cited by this paper
• High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer

  2005cited by this paper
• High Specificity of Quantitative Excision Repair Cross-Complementing 1 Messenger RNA Expression for Prediction of Minor Histopathological Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer

  2004cited by this paper
• Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation.

  2003cited by this paper
• BRCA1: mechanisms of inactivation and implications for management of patients.

  2002cited by this paper
• The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.

  2001cited by this paper
• Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway

  2001cited by this paper
• Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1.

  1999cited by this paper
• Psoriasin (S100A7) expression and invasive breast cancer.

  1999cited by this paper
• Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.

  1994cited by this paper

• A Preliminary Study of NER and MMR Pathways Involved in Chemotherapy Response in Bladder Transitional Cell Carcinoma: Impact on progression-free survival

  2020cites this paper
• Application of dynamic magnetic resonance imaging information technology in adjuvant chemotherapy for breast cancer.

  2020cites this paper
• Predictive Value of Excision Repair Cross-Complementation Group 1 in the Response to Platinum-Based Chemotherapy in Esophageal Cancer: A Meta-Analysis

  2020cites this paper
• Clinical Role of Excision Repair Cross-Complementing 1 Gene Expression in Resected Esophageal Squamous Cell Carcinoma: A Meta-Analysis

  2019cites this paper
• Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer

  2017cites this paper
• Effects of oxaliplatin , leucovorin and fluorouracil on serum tumor markers , VEGF , CRP and matrix metalloproteinases in patients with advanced esophageal cancer

  2017cites this paper
• Sphingosine-1-phosphate/sphingosine kinase 1-dependent lymph node metastasis in esophageal squamous cell carcinoma

  2017cites this paper
• Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy

  2017cites this paper
• Tumor profiling of co-regulated receptor tyrosine kinase and chemoresistant genes reveal different targeting options for lung and gastroesophageal cancers.

  2016cites this paper